Research
Print page Print page
Switch language
Bispebjerg Hospital - a part of Copenhagen University Hospital
Published

The glucose-lowering effect of the bile acid sequestrant sevelamer in patients with type 2 diabetes is not mediated by glucagon-like peptide 1

Research output: Contribution to conferenceConference abstract for conferenceResearchpeer-review

  1. Liraglutide decreases postprandial fibroblast growth factor 19 and glucagon-like peptide 2, and increases postprandial cholecystokinin in individuals with obesity

    Research output: Contribution to conferenceConference abstract for conferenceResearchpeer-review

  2. The Glucagon-Like Peptide-1 Analog, Liraglutide Is a Safe and Effective Treatment of Bile Acid Malabsorption: A Proof of Concept Study

    Research output: Contribution to conferenceConference abstract for conferenceResearchpeer-review

  3. The Glucose-Lowering Effect of the Bile Acid Sequestrant Sevelamer Is Not Mediated by Glucagon-Like Peptide-1

    Research output: Contribution to conferenceConference abstract for conferenceResearchpeer-review

View graph of relations
Original languageEnglish
Publication dateSep 2021
Number of pages1
Publication statusPublished - Sep 2021

ID: 68715065